Company Overview of Nivalis Therapeutics, Inc.
Key Executives for Nivalis Therapeutics, Inc.
|Jon Congleton||13 Relationships||Chief Executive Officer, President and Director||53|
|R. Michael Carruthers||14 Relationships||Chief Financial Officer and Secretary||58|
|Janice M. Troha||No Relationships||Chief Operating Officer and Executive Vice President||58|
|David M. Rodman M.D.||No Relationships||Chief Medical Officer and Executive Vice President of Discovery||--|
Nivalis Therapeutics, Inc. Board Members*
|Name||Board Relationships||Primary Company||Age|
|Howard P. Furst M.D.||18 Relationships||Deerfield Management Company, L.P.||49|
|Jon Congleton||13 Relationships||Nivalis Therapeutics, Inc.||53|
|John R. Moore||13 Relationships||Array BioPharma Inc.||52|
|Robert E. Conway CPA||150 Relationships||ARCA biopharma, Inc.||62|
|Michael A. Marletta Ph.D., M.D.||20 Relationships||The Scripps Research Institute||65|
Nivalis Therapeutics, Inc. Executive Committees*
|Committee Name||Chairperson||Board Relationships||Members|
|Audit Committee CPA||Robert E. Conway||150 Relationships||3 Executives|
|Compensation Committee||John R. Moore||13 Relationships||2 Executives|
|Nominating Committee M.D.||Howard P. Furst||18 Relationships||3 Executives|
|Corporate Governance Committee M.D.||Howard P. Furst||18 Relationships||3 Executives|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
CEO COMPENSATION IN THIS INDUSTRY
|Total Short Term Compensation|
|Total Value of Options||$375.0K|
INDUSTRY EXECUTIVE CHANGES
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.